At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We’re looking for people who are determined to make life better for people around the world.

　　For more than 140 years, Eli Lilly and Company has been dedicated to the discovery and development of medicines to address the health care needs of people around the world. As drug therapies become more complex, Lilly expanded our product capabilities to include the design and development of consumer-friendly, innovative, and award-winning drug delivery systems coupled with our world class drug discovery organization. Driven by the broader, consumer-focused digital revolution in healthcare, Lilly is further expanding the definition of product to include the design, build, integration and orchestration of human factors, smooth injection experiences and digitally-enabled health care interactions. More specifically, we are interested in (1) drug delivery solutions that can be incorporated into our patient centric product creation (2) device designs for making the injection process smooth for our patients; (3) novel bio conjugates; (4) digital health services focused on delivery better outcomes for patients, HCPs and payers, and (5) population management tools. Coupling our medicines, devices, delivery systems, and digital solutions, we believe we can advance in the area of genetic medicines and bioconjugates to enable significant improvements in healthy outcomes for patients.

　　The Targeted delivery & Nanomedicine role within with Drug Delivery & New Product Innovation (DDNPI) group of DDCS (Delivery, Devices, and Connected Solutions) will play a vital role in Lilly’s mission to create next generation therapeutics using new innovative approaches utilizing the foundations of drug delivery, science of injection physiology, application of novel chemistry approaches, together with patient centric drug-device combinations, for the delivery of new modalities including nucleic acid and drug bio conjugates for Lilly’s next generation therapeutics

　　The Targeted delivery and Nanomedicine leader within the DDCS/DDNPI group will work cross functionally with Lilly’s Medicines Innovation Hub (MIH) and Therapeutic area leaders and teams including immunology and genetic medicine with a primary focus to advance drug delivery of new modalities. The Executive Director will develop Chemistry-based approaches for the internal development of new targeted delivery system and also aggressively will seek and evaluates early and late-stage technologies for the delivery of new modalities and bioconjugates through internal development and joint external collaborations. The leader will drive collaboration within DDCS, MIH and Lilly’s core therapeutic areas such as Lilly genetic medicine, immunology, diabetes & Obesity and neuroscience. We are a highly collaborative group that relies on cross functional partnerships and who enjoys networking with and engaging with the external environment from traditional pharmaceutical companies to high technology companies, start-ups, entrepreneurs and academics for novel product creation.

　　Responsibilities:

　　The Executive Director (Targeted delivery, DDCS) will collaborate with R&D leaders across LRL Therapeutic Areas (TAs) Business units and the Medicines Development Unit (MDU) to develop strategy for the delivery of new modalities. This individual will be responsible for supporting TA led initiatives including internal cross functional programs, and external technology based co development in support of targeted delivery. The incumbent will bring chemistry expertise into early development including designing actively targeted delivery systems that address intracellular uptake and efficient release of the cargos including endosomal escape to enable gain/loss of function. The DDCS part of the work will further include leading internal development of targeted delivery systems in collaboration with other functions and TAs and developing characterization methods, bioassays, data analysis, understanding characteristics of delivery systems including barcoding studies and understanding tissue tropism. The leader will also function as the technical lead for external diligences in the area of targeted delivery and provide leadership to drug delivery efforts in other areas including controlled release of peptides/small molecule cargos, and device enabled delivery.

　　The Executive Director will bring chemistry and bio conjugation expertise for the early development of novel drug delivery systems that offers minimal or no off target toxicity through targeted delivery. The leader will advance development of novel chemistry strategies to develop targeted delivery systems through click chemistry, Diels-Alder reaction, bioconjugation, complex formation, and microfluidics technologies.

　　Given the strong synergy between the partnership opportunities in DDCS, MIH functions and TAs, it will be imperative that the Sr./Exe Director stays coordinated with the development goals strategy across all areas. This individual must have a broad understanding of our internal clinical, discovery and technology portfolios in order to be able to strategize and prioritize high-value opportunities. This individual will also have to be a champion of new technologies and chemistry approaches, even when they seem very nascent, to help drive the organization to consider non-traditional approaches in healthcare as the environment in genetic medicine delivery is the need of the hour more rapidly than ever. He/she will also need to be able to leverage a clear understanding of the regulatory environments, pharmaceutical standards of care, routes of administration, patient centricity, critical relationships, and emerging technologies to provide Lilly with the best potential opportunities of strategic interest. Uses strong foundation of technical experience to enrich decision making, identify efficiencies, and increase the probability of technical success of projects and/or capabilities

　　Key Objectives/Deliverables:

　　Play a central role in developing targeted delivery approaches within MIH which incorporates the needs of TAs, and other Lilly organizations and identify potential areas of technical disruption as well as address key gaps within Lilly’s delivery technologies through external collaboration (“skate to where the puck will be”)

　　Challenges the status quo and champions breakthrough approaches to implement novel solutions to scientific issues and/or processes

　　Develop and execute novel targted delivery approaches through internal work via cross functional collaboration with other MIH groups and TAs.

　　Understand immunogenicity and PK/PD aspects of targeted delivery systems including bio distribution, and quantification

　　Develop assays to quntifiy ex vivo and in vivo work for the evaluation of targeted delivery system.

　　Identifies and leads scientific projects/process improvements where solutions are developed by including diverse thinking and experiences from colleagues across the enterprise to deliver outcomes

　　Become extremely familiar with the external environment, for targeted delivery, key issues for various viral and no viral carriers.

　　Develop strategies for targeted delivery to various organs include CNS, liver, lung, and kidneys

　　Understand the competitive environment, both pharma and high tech partners, to anticipate potential areas of disruption to Lilly business models including anticipating the evolution of the competition to gain advantage as it pertains to innovation acquisition and collaborations.

　　Identifies and leads scientific projects/process improvements where solutions are developed by including diverse thinking and experiences from colleagues across the enterprise to deliver outcomes

　　Lead the joint development of delivery strategies by working cros functionally and partnering with ADME groups.

　　Lead and/or participate in visits to external companies with senior leadership, functional groups, business development, and diligence team members

　　Provide inputs to direct reports and manage project activities and basic foundational research

　　Provide mentorship to scientists

　　Leadership in the development of project concepts and execution of these projects when working with external groups including managing or facilitating research collaborations

　　Lead the communication of the results of technical evaluations to internal and external stakeholders, particularly cross-functional senior leadership

　　Ensure integration of efforts through rigorous goal setting, effective teamwork, performance management, collaboration with Lilly groups and a commitment to serving customers both through the BU’s, therapeutic areas and outside the Company.

　　Coach and mentor team member(s), including performance management planning and development, as well as career coaching/mentoring and development. This could include management of team members not co-located with the leader

　　Acts with speed, agility, and decisiveness to identify the critical issues to resolve; influences team and/or key stakeholders on the critical risks and plan for resolution

　　Creates environment for open scientific debate, integrates information and boldly drives to decision or action where no process/precedent exists

　　Champions changes that increase the effectiveness of the overall drug research, development and commercialization

　　Represent DDNPI leadership team.

　　Basic Qualification:

　　PhD in Chemistry or related field.

　　15+ years-experience with at least 10 years in the pharmaceutical industry

　　Bioconjugation experience

　　Experience in nanoparticle-based strategies to improve drug product properties and performance.

　　Additional Preferences:

　　Materials engineering experience (i.e., pH sensitive, stimuli responsive, biodegradable)

　　Experience in targeted cellular and sub-cellular drug delivery

　　Good working knowledge of various ligands for tissue/organ targeting.

　　5-7 years in academics/University with a strong track record of peer reviewed publications, early stage development, external collaboration.

　　Bioconjugate therapeutics, and familiarity with their Pharmacokinetic and pharmacodynamic aspects

　　Ability to solve drug delivery challenges through broad chemistry and materials expertise

　　Demonstrated scientific knowledge of Pharmaceutical Drug development, & Intellectual Property Processes

　　Basic understanding of antibody discovery and protein engineering to articulate the needs of appropriate ligands, nanobodies, and or antibody fragements for efficient targeting.

　　Experience working in a matrix environment as well as leading and leveraging the matrix.

　　Demonstrated ability to work independently as well as in highly integrated cross functional teams.

　　Experience in managing direct reports

　　Develops, motivates, and creates opportunities for others to be highly productive and contribute

　　Additional Information

　　Location: Indianapolis, IN

　　Travel: 20-25% travel is anticipated

　　Eli Lilly and Company, Lilly USA, LLC and our wholly owned subsidiaries (collectively “Lilly”) are committed to help individuals with disabilities to participate in the workforce and ensure equal opportunity to compete for jobs. If you require an accommodation to submit a resume for positions at Lilly, please email Lilly Human Resources ( [email protected] ) for further assistance. Please note This email address is intended for use only to request an accommodation as part of the application process. Any other correspondence will not receive a response.

　　Lilly is an EEO/Affirmative Action Employer and does not discriminate on the basis of age, race, color, religion, gender, sexual orientation, gender identity, gender expression, national origin, protected veteran status, disability or any other legally protected status.

　　Our employee resource groups (ERGs) offer strong support networks for their members and help our company develop talented individuals for future leadership roles. Our current groups include: Africa, Middle East, Central Asia Network, African American Network, Chinese Culture Network, Early Career Professionals, Japanese International Leadership Network (JILN), Lilly India Network, Organization of Latinos at Lilly, PRIDE (LGBTQ + Allies), Veterans Leadership Network, Women’s Network, Working and Living with Disabilities. Learn more about all of our groups.

　　#WeAreLilly